<?xml version="1.0" encoding="iso-8859-1" ?>
<newsitem itemid="545637" id="root" date="1997-04-29" xml:lang="en">
<title>USA: Neurobiological Tech starts Memantine trial.</title>
<headline>Neurobiological Tech starts Memantine trial.</headline>
<dateline>RICHMOND, Calif. 1997-04-29</dateline>
<text>
<p>Neurobiological Technologies Inc on Tuesday said it has begun second Phase II clinical trials of its potential neuroprotectant, Memantine.</p>
<p>The trials will evaluate the analgesic efficacy and safety of Memantine in patients who experience neuropathic pain.</p>
<p>The placebo-controlled double-blind trial is expected to enroll 100 patients at six sites in the United States. It will enroll patients with peripheral neuropathy from diabetes mellitus and patients with post herpetic neuralgia, a chronic pain condition due to shingles. Patients will receive either Memantine or placebo for eight weeks.</p>
</text>
<copyright>(c) Reuters Limited 1997</copyright>
<metadata>
<codes class="bip:countries:1.0">
  <code code="USA">
    <editdetail attribution="Reuters BIP Coding Group" action="confirmed" date="1997-04-29"/>
  </code>
</codes>
<codes class="bip:industries:1.0">
  <code code="I25700">
    <editdetail attribution="Reuters BIP Coding Group" action="confirmed" date="1997-04-29"/>
  </code>
</codes>
<codes class="bip:topics:1.0">
  <code code="C23">
    <editdetail attribution="Reuters BIP Coding Group" action="confirmed" date="1997-04-29"/>
  </code>
  <code code="CCAT">
    <editdetail attribution="Reuters BIP Coding Group" action="confirmed" date="1997-04-29"/>
  </code>
</codes>
<dc element="dc.date.created" value="1997-04-29"/>
<dc element="dc.publisher" value="Reuters Holdings Plc"/>
<dc element="dc.date.published" value="1997-04-29"/>
<dc element="dc.source" value="Reuters"/>
<dc element="dc.creator.location" value="RICHMOND, Calif."/>
<dc element="dc.creator.location.country.name" value="USA"/>
<dc element="dc.source" value="Reuters"/>
</metadata>
</newsitem>
